OrcaGraft

N/A

Report date: 2026/04/30 17:56:15

Base Information

Drug NameOrcaGraft
Drug Alias NameOrca-Q
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrca Biosystems Inc
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityOrca Biosystems Inc
Inactive CompaniesUniversity Of Florida
Active IndicationsMyelodysplastic SyndromesMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis +[4] 
Inactive IndicationsLeukemia, Myeloid, AcuteLeukemia, Myeloid, Accelerated PhaseBlast Crisis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A